Strategies of long-term medication in schizophrenia

被引：0
|
作者：
Gaebel, W [1 ]
机构：
[1] Univ Dusseldorf, Rhein Kliniken Dusseldorf, Klin & Poliklin Psychiat & Psychotherapie, D-40629 Dusseldorf, Germany
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2001年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Schizophrenia is a relapsing disorder. The main goal of neuroleptic long-term treatment is relapse prevention, which is empirically well proven. Availability of different kinds of treatment strategies including new antipsychotic drugs with improved risk/benefit profile allow long-term treatment to be individually tailored. Treatment guidelines developed mainly by the scientific medical societies can help the practitioner in making the right decisions.
引用
收藏
页码：S113 / S119
页数：7
相关论文
共 50 条
  • [31] Under-utilized opportunities to optimize medication management in long-term treatment of schizophrenia
    Isohanni, Matti
    Miettunen, Jouko
    Jaaskelainen, Erika
    Moilanen, Jani
    Hulkko, Anja
    Huhtaniska, Sanna
    WORLD PSYCHIATRY, 2018, 17 (02): : 172 - 173
  • [32] The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia
    Marcela Horvitz-Lennon
    Zachary Predmore
    Patrick Orr
    Mark Hanson
    Richard Hillestad
    Mike Durkin
    Antoine C. El Khoury
    Soeren Mattke
    Administration and Policy in Mental Health and Mental Health Services Research, 2020, 47 : 357 - 365
  • [33] Medication-free research in early episode schizophrenia: Evidence of long-term harm?
    Bola, JR
    SCHIZOPHRENIA BULLETIN, 2006, 32 (02) : 288 - 296
  • [34] The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia
    Horvitz-Lennon, Marcela
    Predmore, Zachary
    Orr, Patrick
    Hanson, Mark
    Hillestad, Richard
    Durkin, Mike
    El Khoury, Antoine C.
    Mattke, Soeren
    ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH, 2020, 47 (03) : 357 - 365
  • [35] Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia
    Ungvari, GS
    Chiu, HFK
    Lam, LCW
    Pang, AHT
    Chung, DWS
    Li, SW
    Chiu, SN
    Lum, FCK
    Leung, T
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) : 141 - 148
  • [36] Executive dysfunction in schizophrenia is not differentially affected by long-term typical or atypical neuroleptic medication
    Rémillard, S
    Pourcher, E
    Cohen, H
    BRAIN AND COGNITION, 2005, 57 (03) : 286 - 286
  • [37] RISK FACTORS FOR NONCOMPLIANCE WITH ANTIPSYCHOTIC MEDICATION IN LONG-TERM TREATED CHRONIC SCHIZOPHRENIA PATIENTS
    Krzystanek, Marek
    Krysta, Krzysztof
    Janas-Kozik, Malgorzata
    Martyniak, Ewa
    Rybakowski, Janusz
    PSYCHIATRIA DANUBINA, 2019, 31 : S543 - S548
  • [38] Long-term efficacy of ADHD medication
    Buitelaar, J.
    Lambregts, N.
    van de Loo, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S134 - S134
  • [39] Long-term effects of maternal medication
    不详
    JOURNAL OF ADVANCED NURSING, 2004, 45 (01) : 108 - 108
  • [40] SAFETY ASPECTS ON LONG-TERM MEDICATION
    LILJESTRAND, A
    ACTA PHARMACEUTICA SUECICA, 1973, 10 (05): : 371 - 380
12345